Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 107 of 6351
-
New drug combo shows promise for rare lung cancer mutation
Disease control OngoingThe purpose of this study is to evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy compared to chemotherapy alone, in patients with locally advanced or metastatic NSCLC with EGFR ex20ins mutations.
Phase 3 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Could a Decades-Old smallpox vaccine stop mpox? colombia trial aims to find out
Prevention OngoingBackground: Mpox is a zoonotic disease caused by the mpox virus (MPXV). It has been endemic in West and Central African countries. However, the soaring number of those has been reported in non-endemic countries since May 2022, making World Health Organization (WHO) declare a glob…
Phase 3 • Sponsor: Universidad Nacional de Colombia • Aim: Prevention
Last updated Jun 26, 2026 14:03 UTC
-
New combo therapy aims to extend life in advanced lung cancer
Disease control Recruiting nowThe primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizu…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Mind-Controlled computer: brain implant gives voice to the paralyzed
Disease control Recruiting nowThe goal of this clinical trial is to demonstrate communication through a brain implant in people in locked-in state, i.e. people with severe paralysis and communication problems. The main questions it aims to answer are efficient and stable control of Brain-Computer interface (…
Sponsor: UMC Utrecht • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Engineered immune cells take on liver cancer in new trial
Disease control OngoingA Phase I/II study to evaluate AZD5851 in patients with GPC3+ advanced/recurrent hepatocellular carcinoma.
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New antibody combo aims to outperform standard lymphoma treatment
Disease control Recruiting nowThis study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with Diffuse Large B-cell Lymphoma (DLBCL) that have not been treated before (called "previously untreated")…
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Gene therapy hope for girls with rare brain disorder
Disease control OngoingThe REVEAL Pediatric Study is a multi-center, Phase 1/2 open-label, dose-escalation and dose-expansion study of TSHA-102, an investigational gene therapy, in pediatric females with Rett Syndrome. The safety, tolerability, and preliminary efficacy of two dose levels will be evalu…
Phase 1/2 • Sponsor: Taysha Gene Therapies, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug aims to outperform chemo for common lymphoma
Disease control Recruiting nowThis study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). This study will be made up of two parts: Part 1 (non-randomi…
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a Dual-Action antibody outsmart resistant tumors?
Disease control Recruiting nowGIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanc…
Phase 1/2 • Sponsor: Georgiamune Inc • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
AI-Powered urine test could revolutionize cervical cancer screening in Low-Income countries
Diagnosis Recruiting nowArtificial intelligence (AI) is fast gaining reputation as a highly promising solution for cervical cancer screening. AI-based detection of cervical neoplasias is named automated visual exam (AVE) by the National Cancer Institute, USA. The investigators propose to develop and eva…
Sponsor: International Agency for Research on Cancer • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
New mRNA vaccine combo aims to stop lung cancer recurrence
Disease control Recruiting nowThe goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-small cell lung cancer (NSCLC). The primary h…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New eye injection could spare sight in melanoma patients
Disease control OngoingThe primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Phase 3 • Sponsor: Aura Biosciences • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug hope for Tough-to-Treat throat cancer
Disease control OngoingA phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with recurrent or metastatic nasopharyngeal carcinoma who had failed at least two lines of platinum-based chemotherapy after receiving PD-1/PD-L1 monoclonal antibody…
Phase 3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New pill takes on hard-to-treat lung cancer in major trial
Disease control By invitation onlyEfficacy and safety evaluation of PLB1004 in patients with locally advanced/metastatic non-squamous NSCLCharboring EGFR exon 20 insertion.
Phase 3 • Sponsor: Avistone Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug shows promise in reversing liver scarring in major trial
Disease control Recruiting nowThis is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.
Phase 3 • Sponsor: Akero Therapeutics, Inc • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can 8 therapy sessions stop a second suicide attempt?
Disease control OngoingSuicide has become a first-order public health concern after the negative impact of coronavirus disease 2019 (COVID-19) on the mental health of the general population. Few studies have analyzed the effects of early psychotherapeutic interventions on subjects who have attempted su…
Sponsor: Hospital Universitari Vall d'Hebron Research Institute • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can new vaccines outsmart COVID-19 variants?
Vaccine CompletedThe purpose of this study is to characterize the safety and immunogenicity of AZD9838 and AZD6563 when administered as a single dose vaccination against SARS-CoV-2 in adults.
Phase 1 • Sponsor: AstraZeneca • Aim: Vaccine
Last updated Sep 02, 2026 00:00 UTC
-
New combo therapy aims to stop High-Risk breast cancer from coming back
Disease control Recruiting nowThis phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with mo…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 01:00 UTC
-
New drug combo CagriSema takes on tirzepatide in obesity showdown
Disease control CompletedThis study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New hope for aggressive breast cancer: drug combo trial launches
Disease control Recruiting nowThis is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive loc…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC